Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients

Clinical Transplantation

Volumn 22, Issue 5, 2008, Pages 549-554

  Sommerer, Claudia ^a   Hartschuh, Wolfgang ^a   Enk, Alexander ^a   Meuer, Stefan ^a   Zeier, Martin ^a   Giese, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Ciclosporin A; Elderly; Immunosuppression; Renal transplantation; Skin cancer

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TRANSCRIPTION FACTOR NFAT;

ADULT; AGE; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; ELDERLY CARE; FEMALE; GENE CONTROL; GENE EXPRESSION; GENETIC MARKER; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PHARMACOGENETICS; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SKIN CANCER; SKIN CARCINOMA; SKIN EXAMINATION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

AGED; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CYCLOSPORINE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NFATC TRANSCRIPTION FACTORS; SKIN NEOPLASMS; SURVIVORS;

EID: 52649095428     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00819.x     Document Type: Article

References (38)

1. Euvrard S, Kanitakis J, Calion A. Skin cancers after organ transplantation. N Engl J Med 2003: 348: 1681.
2. Wimmer CD, Rentsch M, Crispin A et al. The janus face of immunosuppression -de novo malignancy after renal transplantation: The experience of the Transplantation Center Munich. Kidney Int 2007: 71: 1271.
3. Agraharka ML, Cinclair RD, Kuo YF et al. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004: 66: 383.
4. Gutierrez-D almau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs 2007: 67: 1167.
5. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995: 346: 403.
6. Ramsay HM, Fryer AA, Hawley CM et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002: 147: 950.
7. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PF, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant patients. Brit J Dermatol 2006: 154: 498.
8. Fuente MJ, Sabat M, Roca J et al. A prospective study of the incidence of skin cancer and its risk factors in Spanish Mediterranean population of kidney transplant recipients. Br J Dermatol 2003: 149: 1221.
9. Berg D, Oltey CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002: 47: 1.
10. Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004: 15: 1582.
11. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumors posttransplantation: A retrospective analysis of 28years experience at a single centre. Transplant Proc 1997: 29: 828.
12. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000: 342: 605.
13. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: A novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 2004: 19: 55.
14. Giese T, Zeier M, Schemmer P et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: A novel perspective toward individually optimized drug doses of ciclosporin A. Transplantation 2004: 77: 339.
15. Sommerer C, Konstandin M, Schmidt J et al. Pharmacodynamic monitoring of cyclosporin A in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006: 82: 1280.
16. Levey AS, Greene T, Schluchter T et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993: 4: 1159.
17. Cecka JM. The OPTN/UNOS Renal Transplant Registry. Clin Transplant 2005: 19: 1.
18. Holme SA, Malinovszky K, Roberts DL. Changing trends in nonmelanoma skin cancer in South Wales 1988-19998. Br J Dermatol 2000: 143: 1224.
19. De R ijke JM, Shouten LJ, Hillen HF et al. Cancer in the very elderly Dutch population. Cancer 2000: 89: 1121.
20. Euvrard S, Kanitakis J, Pouteil-Noble C et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995: 33: 222.
21. Bordea C, Wojnarowska F, Millard PF, Doll H, Welsh K, Morris PJ. Skin cancers in renal transplant recipients occur more frequently than previously recognized in a temperate climate. Transplanation 2004: 77: 574.
22. Mc Gregor JM, Berkhout RJM, Rozycka M et al. p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status. Oncogene 1997: 15: 1737.
23. Bouwes-Bavinck JN, de Boer A, Vermeer BJ et al. Sunlight, keratotic skin lesions, and skin cancer in renal transplant recipients. Br J Dermatol 1993: 129: 242.
24. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000: 36: 167.
25. Ducloux D, Carron PL, Rebibou JM et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998: 65: 1270.
26. Bouwes-Bavinck JN, Vermeer BJ, van der Woude FJ et al. Relation between skin cancer and HLA antigens in renal-transplant recipients. N Engl J Med 1991: 325: 843.
27. Danovitch GM, Gill J, Bunnapradist S. Immunosuppression of the elderly kidney transplant recipients. Transplantation 2007: 84: 285.
28. Boyle J, Mac Kie RM, Briggs JD, Junor BJ, Aitchison TC. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet 1984: 1: 702.
29. Hojo M, Morimoto T, M aluccio M et al. Ciclosporin induces cancer progression by a cell-autonomous mechanism. Nature 1999: 397: 530.
30. Morris RG, Russ GR, Cervelli MJ et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002: 24: 479.
31. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998: 351: 623.
32. Sommerer C, Hergesell O, Nahm AM et al. Cyclosporin A toxicity of the renal allograft - a late complication and potentially reversible. Nephron 2002: 92: 339.
33. Barten MF, Tarnok A, Barbade J et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007: 40: 50.
34. Stein CM, Murray JJ, Wood AJJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999: 45: 1477.
35. Härtel C, Fricke L, Schuhmacher N, Kirchner H, Müller-Steinhardt M. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: A quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem 2002: 48: 2225.
36. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by ciclosporin in vivo. Transplantation 1999: 68: 1356.
37. Sottong PR, Rosebrock JA, Britz JA, Kramer TR. Measurement of T-lymphocyte responses in whole blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 2000: 10: 67.
38. Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: A new concept of individual immunosuppression. Transplantation 2008: 85: 15.